Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the

Gennaro Daniele, Domenica Lorusso, Giovanni Scambia, Sabrina C. Cecere, Maria Ornella Nicoletto, Enrico Breda, Nicoletta Colombo, Grazia Artioli, Lucia Cannella, Giovanni Lo Re, Francesco Raspagliesi, Giuseppa Maltese, Vanda Salutari, Gabriella Ferrandina, Stefano Greggi, Alessandra Baldoni, Alice Bergamini, Maria Carmela Piccirillo, Germana Tognon, Irene FlorianiSimona Signoriello, Francesco Perrone, Sandro Pignata

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Few data are available on the outcome of surgery after a bevacizumab-containing regimen. The MITO 16A- MaNGO OV2A phase 4 trial evaluates the outcomes of first-line CPB in a clinical-practice-like setting. Here we present the results of the subgroup of patients undergoing IDS after neoadjuvant treatment or suboptimal primary surgery. METHODS: 400 chemonaive epithelial ovarian cancer patients, agetextgreater/=18, ECOG PS 0-2 were eligible to receive C (AUC 5 d1, q21) plus P (175mg/m2 d1, q21) and B (15mg/kg d1 q21) for 6cycles followed by B maintenance until cycle 22nd. RESULTS: 79 patients (20 underwent IDS. Overall, 74 patients received at least one administration of B before IDS. Median age was 61.2, 70% of the patients had FIGO IIIC disease. The median number of cycles before IDS was 3 both for chemotherapy and bevacizumab respectively. A residual disease textless/=1cm was achieved in 64 patients (86.5. Four percent of the patients experienced fever and 4% required blood transfusion after surgery. Surgical wound infection and/or dehiscence, pelvic abscess, intestinal sub-occlusion and fistula were experienced by one patient each. CONCLUSIONS: In the MITO16A-MaNGO OV2A phase 4 trial, combined chemotherapy and bevacizumab did not hamper IDS and the rate of perioperative complications was similar to what expected without bevacizumab. These data support the hypothesis that adding bevacizumab to first line chemotherapy for ovarian cancer might not be denied to patients for whom IDS is planned.
Original languageUndefined/Unknown
Pages (from-to)256-259
Number of pages4
JournalGynecologic Oncology
Volume144
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Keywords

  • Bevacizumab, Interval debulking, Neoadjuvant, Ovarian cancer, Surgery

Cite this

Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the. / Daniele, Gennaro; Lorusso, Domenica; Scambia, Giovanni; Cecere, Sabrina C.; Nicoletto, Maria Ornella; Breda, Enrico; Colombo, Nicoletta; Artioli, Grazia; Cannella, Lucia; Lo Re, Giovanni; Raspagliesi, Francesco; Maltese, Giuseppa; Salutari, Vanda; Ferrandina, Gabriella; Greggi, Stefano; Baldoni, Alessandra; Bergamini, Alice; Piccirillo, Maria Carmela; Tognon, Germana; Floriani, Irene; Signoriello, Simona; Perrone, Francesco; Pignata, Sandro.

In: Gynecologic Oncology, Vol. 144, No. 2, 01.02.2017, p. 256-259.

Research output: Contribution to journalArticle

Daniele, Gennaro ; Lorusso, Domenica ; Scambia, Giovanni ; Cecere, Sabrina C. ; Nicoletto, Maria Ornella ; Breda, Enrico ; Colombo, Nicoletta ; Artioli, Grazia ; Cannella, Lucia ; Lo Re, Giovanni ; Raspagliesi, Francesco ; Maltese, Giuseppa ; Salutari, Vanda ; Ferrandina, Gabriella ; Greggi, Stefano ; Baldoni, Alessandra ; Bergamini, Alice ; Piccirillo, Maria Carmela ; Tognon, Germana ; Floriani, Irene ; Signoriello, Simona ; Perrone, Francesco ; Pignata, Sandro. / Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the. In: Gynecologic Oncology. 2017 ; Vol. 144, No. 2. pp. 256-259.
@article{9164a7efc34646f78819743b00d90e88,
title = "Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the",
abstract = "BACKGROUND: Few data are available on the outcome of surgery after a bevacizumab-containing regimen. The MITO 16A- MaNGO OV2A phase 4 trial evaluates the outcomes of first-line CPB in a clinical-practice-like setting. Here we present the results of the subgroup of patients undergoing IDS after neoadjuvant treatment or suboptimal primary surgery. METHODS: 400 chemonaive epithelial ovarian cancer patients, agetextgreater/=18, ECOG PS 0-2 were eligible to receive C (AUC 5 d1, q21) plus P (175mg/m2 d1, q21) and B (15mg/kg d1 q21) for 6cycles followed by B maintenance until cycle 22nd. RESULTS: 79 patients (20 underwent IDS. Overall, 74 patients received at least one administration of B before IDS. Median age was 61.2, 70{\%} of the patients had FIGO IIIC disease. The median number of cycles before IDS was 3 both for chemotherapy and bevacizumab respectively. A residual disease textless/=1cm was achieved in 64 patients (86.5. Four percent of the patients experienced fever and 4{\%} required blood transfusion after surgery. Surgical wound infection and/or dehiscence, pelvic abscess, intestinal sub-occlusion and fistula were experienced by one patient each. CONCLUSIONS: In the MITO16A-MaNGO OV2A phase 4 trial, combined chemotherapy and bevacizumab did not hamper IDS and the rate of perioperative complications was similar to what expected without bevacizumab. These data support the hypothesis that adding bevacizumab to first line chemotherapy for ovarian cancer might not be denied to patients for whom IDS is planned.",
keywords = "Bevacizumab, Interval debulking, Neoadjuvant, Ovarian cancer, Surgery",
author = "Gennaro Daniele and Domenica Lorusso and Giovanni Scambia and Cecere, {Sabrina C.} and Nicoletto, {Maria Ornella} and Enrico Breda and Nicoletta Colombo and Grazia Artioli and Lucia Cannella and {Lo Re}, Giovanni and Francesco Raspagliesi and Giuseppa Maltese and Vanda Salutari and Gabriella Ferrandina and Stefano Greggi and Alessandra Baldoni and Alice Bergamini and Piccirillo, {Maria Carmela} and Germana Tognon and Irene Floriani and Simona Signoriello and Francesco Perrone and Sandro Pignata",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.ygyno.2016.12.011",
language = "Non definita",
volume = "144",
pages = "256--259",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the

AU - Daniele, Gennaro

AU - Lorusso, Domenica

AU - Scambia, Giovanni

AU - Cecere, Sabrina C.

AU - Nicoletto, Maria Ornella

AU - Breda, Enrico

AU - Colombo, Nicoletta

AU - Artioli, Grazia

AU - Cannella, Lucia

AU - Lo Re, Giovanni

AU - Raspagliesi, Francesco

AU - Maltese, Giuseppa

AU - Salutari, Vanda

AU - Ferrandina, Gabriella

AU - Greggi, Stefano

AU - Baldoni, Alessandra

AU - Bergamini, Alice

AU - Piccirillo, Maria Carmela

AU - Tognon, Germana

AU - Floriani, Irene

AU - Signoriello, Simona

AU - Perrone, Francesco

AU - Pignata, Sandro

PY - 2017/2/1

Y1 - 2017/2/1

N2 - BACKGROUND: Few data are available on the outcome of surgery after a bevacizumab-containing regimen. The MITO 16A- MaNGO OV2A phase 4 trial evaluates the outcomes of first-line CPB in a clinical-practice-like setting. Here we present the results of the subgroup of patients undergoing IDS after neoadjuvant treatment or suboptimal primary surgery. METHODS: 400 chemonaive epithelial ovarian cancer patients, agetextgreater/=18, ECOG PS 0-2 were eligible to receive C (AUC 5 d1, q21) plus P (175mg/m2 d1, q21) and B (15mg/kg d1 q21) for 6cycles followed by B maintenance until cycle 22nd. RESULTS: 79 patients (20 underwent IDS. Overall, 74 patients received at least one administration of B before IDS. Median age was 61.2, 70% of the patients had FIGO IIIC disease. The median number of cycles before IDS was 3 both for chemotherapy and bevacizumab respectively. A residual disease textless/=1cm was achieved in 64 patients (86.5. Four percent of the patients experienced fever and 4% required blood transfusion after surgery. Surgical wound infection and/or dehiscence, pelvic abscess, intestinal sub-occlusion and fistula were experienced by one patient each. CONCLUSIONS: In the MITO16A-MaNGO OV2A phase 4 trial, combined chemotherapy and bevacizumab did not hamper IDS and the rate of perioperative complications was similar to what expected without bevacizumab. These data support the hypothesis that adding bevacizumab to first line chemotherapy for ovarian cancer might not be denied to patients for whom IDS is planned.

AB - BACKGROUND: Few data are available on the outcome of surgery after a bevacizumab-containing regimen. The MITO 16A- MaNGO OV2A phase 4 trial evaluates the outcomes of first-line CPB in a clinical-practice-like setting. Here we present the results of the subgroup of patients undergoing IDS after neoadjuvant treatment or suboptimal primary surgery. METHODS: 400 chemonaive epithelial ovarian cancer patients, agetextgreater/=18, ECOG PS 0-2 were eligible to receive C (AUC 5 d1, q21) plus P (175mg/m2 d1, q21) and B (15mg/kg d1 q21) for 6cycles followed by B maintenance until cycle 22nd. RESULTS: 79 patients (20 underwent IDS. Overall, 74 patients received at least one administration of B before IDS. Median age was 61.2, 70% of the patients had FIGO IIIC disease. The median number of cycles before IDS was 3 both for chemotherapy and bevacizumab respectively. A residual disease textless/=1cm was achieved in 64 patients (86.5. Four percent of the patients experienced fever and 4% required blood transfusion after surgery. Surgical wound infection and/or dehiscence, pelvic abscess, intestinal sub-occlusion and fistula were experienced by one patient each. CONCLUSIONS: In the MITO16A-MaNGO OV2A phase 4 trial, combined chemotherapy and bevacizumab did not hamper IDS and the rate of perioperative complications was similar to what expected without bevacizumab. These data support the hypothesis that adding bevacizumab to first line chemotherapy for ovarian cancer might not be denied to patients for whom IDS is planned.

KW - Bevacizumab, Interval debulking, Neoadjuvant, Ovarian cancer, Surgery

U2 - 10.1016/j.ygyno.2016.12.011

DO - 10.1016/j.ygyno.2016.12.011

M3 - Articolo

VL - 144

SP - 256

EP - 259

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -